184 related articles for article (PubMed ID: 28009354)
1. RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts.
Gieseler-Halbach S; Meltendorf S; Pierau M; Weinert S; Heidel FH; Fischer T; Handschuh J; Braun-Dullaeus RC; Schrappe M; Lindquist JA; Mertens PR; Thomas U; Brunner-Weinzierl MC
Cell Death Differ; 2017 Feb; 24(2):371-383. PubMed ID: 28009354
[TBL] [Abstract][Full Text] [Related]
2. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858
[TBL] [Abstract][Full Text] [Related]
4. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
[TBL] [Abstract][Full Text] [Related]
5. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
[TBL] [Abstract][Full Text] [Related]
6. Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase.
Tiwari A; Rebholz S; Maier E; Dehghan Harati M; Zips D; Sers C; Rodemann HP; Toulany M
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126195
[TBL] [Abstract][Full Text] [Related]
7. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
8. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous Targeting of RSK and AKT Efficiently Inhibits YB-1-Mediated Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks in Breast Cancer Cells.
Lettau K; Zips D; Toulany M
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):567-580. PubMed ID: 32931865
[TBL] [Abstract][Full Text] [Related]
10. Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models.
Sechi M; Lall RK; Afolabi SO; Singh A; Joshi DC; Chiu SY; Mukhtar H; Syed DN
Sci Rep; 2018 Oct; 8(1):15726. PubMed ID: 30356079
[TBL] [Abstract][Full Text] [Related]
11. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.
Yu YN; Yip GW; Tan PH; Thike AA; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2010 Aug; 37(2):483-92. PubMed ID: 20596676
[TBL] [Abstract][Full Text] [Related]
12. MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop.
Sinnberg T; Sauer B; Holm P; Spangler B; Kuphal S; Bosserhoff A; Schittek B
Exp Dermatol; 2012 Apr; 21(4):265-70. PubMed ID: 22417301
[TBL] [Abstract][Full Text] [Related]
13. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
14. Cell Survival Failure in Effector T Cells From Patients With Systemic Lupus Erythematosus Following Insufficient Up-Regulation of Cold-Shock Y-Box Binding Protein 1.
Meltendorf S; Fu H; Pierau M; Lindquist JA; Finzel S; Mertens PR; Gieseler-Halbach S; Ambach A; Thomas U; Lingel H; Voll RE; Brunner-Weinzierl MC
Arthritis Rheumatol; 2020 Oct; 72(10):1721-1733. PubMed ID: 32475063
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Y-box Binding Protein-1 Axis to Overcome Radiochemotherapy Resistance in Solid Tumors.
Lettau K; Khozooei S; Kosnopfel C; Zips D; Schittek B; Toulany M
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):1072-1087. PubMed ID: 34166770
[TBL] [Abstract][Full Text] [Related]
16. Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma.
Miao X; Wu Y; Wang Y; Zhu X; Yin H; He Y; Li C; Liu Y; Lu X; Chen Y; Shen R; Xu X; He S
Exp Cell Res; 2016 Aug; 346(2):157-66. PubMed ID: 27397581
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation by Akt disables the anti-oncogenic activity of YB-1.
Bader AG; Vogt PK
Oncogene; 2008 Feb; 27(8):1179-82. PubMed ID: 17704806
[TBL] [Abstract][Full Text] [Related]
18. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.
Smith JA; Poteet-Smith CE; Xu Y; Errington TM; Hecht SM; Lannigan DA
Cancer Res; 2005 Feb; 65(3):1027-34. PubMed ID: 15705904
[TBL] [Abstract][Full Text] [Related]
19. Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma.
Fujiwara-Okada Y; Matsumoto Y; Fukushi J; Setsu N; Matsuura S; Kamura S; Fujiwara T; Iida K; Hatano M; Nabeshima A; Yamada H; Ono M; Oda Y; Iwamoto Y
Br J Cancer; 2013 Mar; 108(4):836-47. PubMed ID: 23462806
[TBL] [Abstract][Full Text] [Related]
20. YB-1 Oncoprotein Controls PI3K/Akt Pathway by Reducing Pten Protein Level.
Delicato A; Montuori E; Angrisano T; Pollice A; Calabrò V
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
